HCC33Homo sapiens (Human)Cancer cell line

Also known as: Hamon Cancer Center 33, HCC0033, HCC-33

🤖 AI SummaryBased on 10 publications

Quick Overview

Human lung cancer cell line with known mutations and genomic features.

Detailed Summary

HCC33 is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is widely used in cancer research to study the molecular mechanisms of tumorigenesis and drug resistance. The cell line has been characterized for its genetic alterations, including mutations in key oncogenes and tumor suppressor genes, which are critical for understanding cancer progression. Research on HCC33 has contributed to the identification of potential therapeutic targets and the development of targeted therapies. The cell line is also utilized in studies involving gene expression profiling and the analysis of signaling pathways involved in cancer development.

Research Applications

Molecular mechanisms of tumorigenesisDrug resistance studiesGenetic alterations analysisOncogene and tumor suppressor gene mutationsGene expression profilingSignaling pathway analysis

Key Characteristics

Mutations in key oncogenesCharacterized for genomic featuresUsed in targeted therapy development
Generated on 6/18/2025

Basic Information

Database IDCVCL_2058
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age52
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseSmall cell lung cancer
LineageLung
SubtypeSmall Cell Lung Cancer
OncoTree CodeSCLC

DepMap Information

Source TypeDSMZ
Source IDACH-000515_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Cys242Tyr (c.725G>A)Unspecified-PubMed=32784519
MutationSimpleRB1p.Ser402fs*8 (c.1202delT) (p.I401fs)Heterozygous-Unknown, Unknown
Gene fusionRLFRLF-UBE2J2--PubMed=23716474
Gene fusionC1QTNF12RLF-C1QTNF12, RLF-FAM132A--PubMed=23716474

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D13S317
11,13
D16S539
11,12
D18S51
12,17
D19S433
14,15
D21S11
30,32
D2S1338
16,25
D3S1358
16
D5S818
11
D7S820
11
D8S1179
13,14
FGA
20,23
Penta D
10,12
Penta E
14
TH01
9
TPOX
8,11
vWA
16,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer.

Yokota J.

Genes Chromosomes Cancer 52:802-816(2013).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Lung cancer cell lines as tools for biomedical discovery and research.

Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.

J. Natl. Cancer Inst. 102:1310-1321(2010).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.

Minna J.D.

Oncogene 20:1005-1009(2001).

Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.

Girard L., Zochbauer-Muller S., Virmani A.K., Gazdar A.F., Minna J.D.

Cancer Res. 60:4894-4906(2000).

Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types.

Minna J.D., Gazdar A.F.

Genes Chromosomes Cancer 21:308-319(1998).

Web Resources